A team at UHP helps enhance patient care thanks to breakthrough in anaemia treatment
University Hospitals Plymouth NHS Trust is leading the way in innovative care for patients with anaemia, a common complication of chronic kidney disease (CKD).
Thanks to the efforts of Antony Mitchell, Lead Pharmacist for Urgent and Emergency Care, Karla Purtill, Lead Nurse for Chronic Kidney Disease, and their teams, the Trust has introduced new approaches that are improving patient outcomes, reducing hospital visits, and streamlining care pathways.
A patient-centered approach
Anaemia, often associated with renal failure, can be debilitating for patients. The team at UHP recognised the need for more effective and patient-friendly treatments. Partnering with Pharma Cosmos, w
ho specialise in the treatment of anaemia, the team evaluated a new treatment option; ferric derisomaltose (FDI). Unlike the previous treatment, ferric carboxymaltose (FCM), FDI is tailored to each patient based on height and ideal body weight, providing more individualised care. This means fewer repeat infusions, longer-lasting effects, and less stress for patients.
“Patients are very pleased with the outcome,” said Karla. “Instead of having to come to the hospital twice for their iron infusions, many now only need a single visit. It’s not just about convenience; the tailored approach is improving the effectiveness of the treatment and overall patient satisfaction.”
Improving efficiency and sustainability
The transition to FDI has not only benefitted patients but also the Trust. By reducing the number of hospital visits, the team has eased the demand on outpatient services, cut costs associated with repeated infusions, and contributed to a more sustainable healthcare environment. These changes align with the Trust’s goals of reducing carbon emissions and enhancing the efficiency of its services.
Karla and her colleagues conducted an audit of the new treatment pathway, presenting their findings at UK Kidney Week in Edinburgh earlier this year. The results highlighted significant improvements in patient response rates and cost-effectiveness, cementing FDI as the first-line treatment for anaemia in renal patients at the Trust. “This work has not only improved care but also showcased our commitment to innovation and excellence,” added Karla.
Collaborative pathways across specialties
Building on the success of the renal guidelines, the team collaborated with pharmacists and acute medicine specialists to expand the use of FDI across other specialties. This cross-disciplinary approach ensures that both acute and chronic anaemia patients benefit from the same high standards of care. “We’re creating pathways that are seamless and patient-focused,” explained Karla. “By ensuring appropriate referrals and streamlining processes, we’re enhancing the overall experience for patients and improving efficiency for staff.”
Looking ahead
The team is now exploring new ways to further improve anaemia management. Plans are underway to develop a patient-initiated follow-up (PIFU) pathway, which will empower patients to access care when they need it, rather than through routine appointments. This approach could reduce unnecessary referrals and waiting times, while maintaining high-quality care.
The innovative work by Antony, Karla and their teams have gained international recognition. At the recent World Anaemia Day conference in Copenhagen, they shared insights and learned from global leaders in anaemia management. “It was fascinating to see how other specialties and countries approach anaemia,” said Karla. “It reaffirmed that our work at Plymouth is truly ahead of the curve.”
Celebrating success
This achievement is a testament to the dedication and hard work of the anaemia care team at UHP. By prioritising patient needs, embracing innovation, and fostering collaboration, they have set a new standard in anaemia treatment. Their efforts continue to make a tangible difference in the lives of patients and reinforce the Trust’s reputation for excellence in renal care as well as the management of iron deficiency anaemia.
